Pulmonx stock has seen its consensus fair value remain steady at $5.75 per share following a recent update to its narrative. Although the price target is unchanged, investors are watching closely, as ...

Pulmonx Corp (LUNG) reports a 5% revenue increase despite slowed US growth and rising expenses, focusing on strategic ...

Pulmonx Corporation ( ($LUNG) ) has released its Q3 earnings. Here is a breakdown of the information Pulmonx Corporation presented to its ...

Q3 2025 Earnings Call November 12, 2025 4:30 PM ESTCompany ParticipantsGlendon French - CEO, President & DirectorDerrick ...

Reports Q3 revenue $21.5M, consensus $20.9M. “While our third quarter performance broadly met expectations, we feel there is a meaningful ...

Pulmonx Corporation (Nasdaq: LUNG) ('Pulmonx” or the 'Company'), a global leader in minimally invasive treatments for lung ...

Pulmonx is positioned at the bottom for Revenue Growth, with a negative growth rate. It is also at the bottom for Gross ...

Compared with the early-1960s, there are now around seven times as many vehicles competing for space on Australia’s roads. So ...

Pulmonx Corporation (NASDAQ:LUNG) is one of the best stocks under $3 to invest in. On October 28, Lake Street lowered the firm’s price target on Pulmonx to $4 from $8 and kept a Buy rating on the ...

On October 16, Victoria Greene, Chief Investment Officer of G Squared Private Wealth Management, appeared on CNBC to state that small caps demonstrate lasting strength. Greene explained that investors ...